Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

PURPOSE: BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-x(l) and BCL-w, potently inducing apoptosis of CLL cells in vitro. A phase I trial in patients with CLL was conducted to ev...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Roberts, Andrew W., Seymour, John F., Brown, Jennifer R., Wierda, William G., Kipps, Thomas J., Khaw, Seong Lin, Carney, Dennis A., He, Simon Z., Huang, David C.S., Xiong, Hao, Cui, Yue, Busman, Todd A., McKeegan, Evelyn M., Krivoshik, Andrew P., Enschede, Sari H., Humerickhouse, Rod
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2012
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979082/
https://ncbi.nlm.nih.gov/pubmed/22184378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.34.7898
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars